# Systemic anti-cancer therapy for advanced non-small-cell lung cancer: accessible summary

8 March 2024

## Squamous non-small cell lung cancer, no targetable mutations, PD‑L1 below 50%

Initial recommended treatment options are:

* platinum doublet chemotherapy or
* the [NICE technology appraisal guidance on pembrolizumab with carboplatin and paclitaxel](https://www.nice.org.uk/guidance/ta770).

For people who have disease progression after initial treatment with platinum doublet chemotherapy, recommended treatment options are:

* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428) (if PD-L1 above 1%) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta520) (any PD-L1 0% to 100%) or
* the [NICE technology appraisal guidance on nivolumab](https://www.nice.org.uk/guidance/ta655) (any PD-L1 0% to 100%) or
* docetaxel.

For people who have had initial treatment with platinum doublet chemotherapy and who have disease progression after treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428), [atezolizumab](https://www.nice.org.uk/guidance/ta520) or [nivolumab](https://www.nice.org.uk/guidance/ta655), the only recommended treatment option is docetaxel.

For people who have had initial treatment with platinum doublet chemotherapy and who have disease progression after treatment with docetaxel, recommended treatment options are:

* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428) (if PD-L1 above 1%) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta520) (any PD-L1 0% to 100%) or
* the [NICE technology appraisal guidance on nivolumab](https://www.nice.org.uk/guidance/ta655) (any PD-L1 0% to 100%).

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab with carboplatin and paclitaxel](https://www.nice.org.uk/guidance/ta770), the only recommended treatment option is docetaxel.

## Squamous non-small cell lung cancer, no targetable mutations, PD‑L1 50% or higher

Initial recommended treatment options are:

* the [NICE technology appraisal guidance on pembrolizumab with carboplatin and paclitaxel](https://www.nice.org.uk/guidance/ta770) (only if urgent clinical intervention is needed) or
* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta531) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta705).

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab with carboplatin and paclitaxel](https://www.nice.org.uk/guidance/ta770), the only recommended treatment option is docetaxel.

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta531) or [atezolizumab](https://www.nice.org.uk/guidance/ta705), the only recommended treatment option is platinum doublet chemotherapy.

For people who have disease progression after platinum doublet chemotherapy, the only recommended treatment option is docetaxel.

## Squamous non-small cell lung cancer, RET fusion positive, PD‑L1 below 50%

Initial recommended treatment options are:

* platinum doublet chemotherapy or
* the [NICE technology appraisal guidance on pembrolizumab with carboplatin and paclitaxel](https://www.nice.org.uk/guidance/ta770) or
* the [NICE technology appraisal guidance on selpercatinib](https://www.nice.org.uk/guidance/indevelopment/gid-ta11012).

For people who have disease progression after initial treatment with platinum doublet chemotherapy, recommended treatment options are:

* the [NICE technology appraisal guidance on selpercatinib](https://www.nice.org.uk/guidance/ta760) (available through the Cancer Drugs Fund) or
* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428) (if PD-L1 above 1%) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta520) (any PD-L1 0% to 100%) or
* the [NICE technology appraisal guidance on nivolumab](https://www.nice.org.uk/guidance/ta655) (any PD-L1 0% to 100%) or
* docetaxel.

For people who have had initial treatment with platinum doublet chemotherapy and who have disease progression after treatment in line with the [NICE technology appraisal guidance on selpercatinib](https://www.nice.org.uk/guidance/ta760), recommended treatment options are:

* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428) (if PD-L1 above 1%) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta520) (any PD-L1 0% to 100%) or
* the [NICE technology appraisal guidance on nivolumab](https://www.nice.org.uk/guidance/ta655) (any PD-L1 0% to 100%) or
* docetaxel.

For people who have had treatment in line with the [NICE technology appraisal guidance on selpercatinib](https://www.nice.org.uk/guidance/ta760) and who have disease progression after follow-up treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428), [atezolizumab](https://www.nice.org.uk/guidance/ta520) or [nivolumab](https://www.nice.org.uk/guidance/ta655), the only recommended treatment option is docetaxel (NHS England policy).

For people who have had treatment in line with the [NICE technology appraisal guidance on selpercatinib](https://www.nice.org.uk/guidance/ta760) and who have disease progression after follow-up treatment with docetaxel, recommended treatment options (NHS England policy) are:

* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428) (if PD-L1 above 1%) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta520) (any PD-L1 0% to 100%) or
* the [NICE technology appraisal guidance on nivolumab](https://www.nice.org.uk/guidance/ta655) (any PD-L1 0% to 100%).

For people who have had initial treatment with platinum doublet chemotherapy and who have disease progression after treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428), [atezolizumab](https://www.nice.org.uk/guidance/ta520) or [nivolumab](https://www.nice.org.uk/guidance/ta655), recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on selpercatinib](https://www.nice.org.uk/guidance/ta760) (available through the Cancer Drugs Fund).

For people who have had treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428), [atezolizumab](https://www.nice.org.uk/guidance/ta520) or [nivolumab](https://www.nice.org.uk/guidance/ta655), and who have disease progression after follow-up treatment with docetaxel, the only recommended treatment option is the [NICE technology appraisal guidance on selpercatinib](https://www.nice.org.uk/guidance/ta760) (available through the Cancer Drugs Fund; NHS England policy).

For people who have had treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428), [atezolizumab](https://www.nice.org.uk/guidance/ta520) or [nivolumab](https://www.nice.org.uk/guidance/ta655), and who have disease progression after follow-up treatment in line with the [NICE technology appraisal guidance on selpercatinib](https://www.nice.org.uk/guidance/ta760), the only recommended treatment option is docetaxel.

For people who have had initial treatment with platinum doublet chemotherapy and who have disease progression after treatment with docetaxel, recommended treatment options are:

* the [NICE technology appraisal guidance on selpercatinib](https://www.nice.org.uk/guidance/ta760) (available through the Cancer Drugs Fund; NHS England policy) or
* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428) (if PD-L1 above 1%) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta520) (any PD-L1 0% to 100%) or
* the [NICE technology appraisal guidance on nivolumab](https://www.nice.org.uk/guidance/ta655) (any PD-L1 0% to 100%).

For people who have had treatment with docetaxel and who have disease progression after follow-up treatment in line with the [NICE technology appraisal guidance on selpercatinib](https://www.nice.org.uk/guidance/ta760), recommended treatment options (NHS England policy) are:

* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428) (if PD-L1 above 1%) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta520) (any PD-L1 0% to 100%) or
* the [NICE technology appraisal guidance on nivolumab](https://www.nice.org.uk/guidance/ta655) (any PD-L1 0% to 100%).

For people who have had treatment with docetaxel and who have disease progression after follow-up treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428), [atezolizumab](https://www.nice.org.uk/guidance/ta520) or [nivolumab](https://www.nice.org.uk/guidance/ta655), the only recommended treatment option is the [NICE technology appraisal guidance on selpercatinib](https://www.nice.org.uk/guidance/ta760) (available through the Cancer Drugs Fund).

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab with carboplatin and paclitaxel](https://www.nice.org.uk/guidance/ta770), recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on selpercatinib](https://www.nice.org.uk/guidance/ta760) (available through the Cancer Drugs Fund).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab with carboplatin and paclitaxel](https://www.nice.org.uk/guidance/ta770) and who have disease progression after treatment with docetaxel, the only recommended treatment option is the [NICE technology appraisal guidance on selpercatinib](https://www.nice.org.uk/guidance/ta760) (available through the Cancer Drugs Fund; NHS England policy).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab with carboplatin and paclitaxel](https://www.nice.org.uk/guidance/ta770) and who have disease progression after treatment in line with the [NICE technology appraisal guidance on selpercatinib](https://www.nice.org.uk/guidance/ta760), the only recommended treatment option is docetaxel.

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on selpercatinib](https://www.nice.org.uk/guidance/indevelopment/gid-ta11012), the only recommended treatment option is platinum doublet chemotherapy (NHS England policy).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on selpercatinib](https://www.nice.org.uk/guidance/indevelopment/gid-ta11012) and who have disease progression after treatment with platinum doublet chemotherapy, recommended treatment options are:

* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428) (if PD-L1 above 1%) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta520) (any PD-L1 0% to 100%) or
* the [NICE technology appraisal guidance on nivolumab](https://www.nice.org.uk/guidance/ta655) (any PD-L1 0% to 100%) or
* docetaxel (NHS England policy).

For people who have had treatment with platinum doublet chemotherapy and who have disease progression after follow-up treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428), [atezolizumab](https://www.nice.org.uk/guidance/ta520) or [nivolumab](https://www.nice.org.uk/guidance/ta655), the only recommended treatment option is docetaxel.

For people who have had treatment with platinum doublet chemotherapy and who have disease progression after treatment with docetaxel, recommended treatment options are:

* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428) (if PD-L1 above 1%) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta520) (any PD-L1 0% to 100%) or
* the [NICE technology appraisal guidance on nivolumab](https://www.nice.org.uk/guidance/ta655) (any PD-L1 0% to 100%).

## Squamous non-small cell lung cancer, RET fusion positive, PD‑L1 50% or higher

Initial recommended treatment options are:

* the [NICE technology appraisal guidance on pembrolizumab with carboplatin and paclitaxel](https://www.nice.org.uk/guidance/ta770) (only if urgent clinical intervention is needed) or
* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta531) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta705) or
* the [NICE technology appraisal guidance on selpercatinib](https://www.nice.org.uk/guidance/indevelopment/gid-ta11012).

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab with carboplatin and paclitaxel](https://www.nice.org.uk/guidance/ta770), recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on selpercatinib](https://www.nice.org.uk/guidance/ta760) (available through the Cancer Drugs Fund).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab with carboplatin and paclitaxel](https://www.nice.org.uk/guidance/ta770) and who have disease progression after treatment with docetaxel, the only recommended treatment option is the [NICE technology appraisal guidance on selpercatinib](https://www.nice.org.uk/guidance/ta760) (available through the Cancer Drugs Fund; NHS England policy).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab with carboplatin and paclitaxel](https://www.nice.org.uk/guidance/ta770) and who have disease progression after treatment in line with the [NICE technology appraisal guidance on selpercatinib](https://www.nice.org.uk/guidance/ta760), the only recommended treatment option is docetaxel.

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta531) or [atezolizumab](https://www.nice.org.uk/guidance/ta705), recommended treatment options are:

* platinum doublet chemotherapy or
* the [NICE technology appraisal guidance on selpercatinib](https://www.nice.org.uk/guidance/ta760) (available through the Cancer Drugs Fund).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta531) or [atezolizumab](https://www.nice.org.uk/guidance/ta705) and who have disease progression after treatment with platinum doublet chemotherapy, recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on selpercatinib](https://www.nice.org.uk/guidance/ta760) (available through the Cancer Drugs Fund).

For people who have had platinum doublet chemotherapy and who have disease progression after follow-up treatment with docetaxel, the only recommended treatment option is the [NICE technology appraisal guidance on selpercatinib](https://www.nice.org.uk/guidance/ta760) (available through the Cancer Drugs Fund; NHS England policy).

For people who have had platinum doublet chemotherapy and who have disease progression after follow-up treatment in line with the [NICE technology appraisal guidance on selpercatinib](https://www.nice.org.uk/guidance/ta760), the only recommended treatment option is docetaxel.

For people who have had initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta531) or [atezolizumab](https://www.nice.org.uk/guidance/ta705) and who have disease progression after treatment in line with the [NICE technology appraisal guidance on selpercatinib](https://www.nice.org.uk/guidance/ta760), recommended treatment options are:

* docetaxel or
* platinum doublet chemotherapy.

For people who had treatment in line with the [NICE technology appraisal guidance on selpercatinib](https://www.nice.org.uk/guidance/ta760) and who have disease progression after follow-up treatment with docetaxel, the only recommended treatment option is platinum doublet chemotherapy.

For people who had treatment in line with the [NICE technology appraisal guidance on selpercatinib](https://www.nice.org.uk/guidance/ta760) and who have disease progression after follow-up treatment with platinum doublet chemotherapy, the only recommended treatment option is docetaxel.

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on selpercatinib](https://www.nice.org.uk/guidance/indevelopment/gid-ta11012), the only recommended treatment option is platinum doublet chemotherapy (NHS England policy).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on selpercatinib](https://www.nice.org.uk/guidance/indevelopment/gid-ta11012) and who have disease progression after treatment with platinum doublet chemotherapy, recommended treatment options are:

* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428) (if PD-L1 above 1%) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta520) (any PD-L1 0% to 100%) or
* the [NICE technology appraisal guidance on nivolumab](https://www.nice.org.uk/guidance/ta655) (any PD-L1 0% to 100%) or
* docetaxel (NHS England policy).

For people who have had treatment with platinum doublet chemotherapy and who have disease progression after follow-up treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428), [atezolizumab](https://www.nice.org.uk/guidance/ta520) or [nivolumab](https://www.nice.org.uk/guidance/ta655), the only recommended treatment option is docetaxel.

For people who have had treatment with platinum doublet chemotherapy and who have disease progression after treatment with docetaxel, recommended treatment options are:

* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428) (if PD-L1 above 1%) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta520) (any PD-L1 0% to 100%) or
* the [NICE technology appraisal guidance on nivolumab](https://www.nice.org.uk/guidance/ta655) (any PD-L1 0% to 100%).

## Squamous non-small cell lung cancer, NTRK fusion positive, PD‑L1 below 50%

Initial recommended treatment options are:

* platinum doublet chemotherapy or
* the [NICE technology appraisal guidance on pembrolizumab with carboplatin and paclitaxel](https://www.nice.org.uk/guidance/ta770).

For people who have disease progression after initial treatment with platinum doublet chemotherapy, recommended treatment options are:

* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428) (if PD-L1 above 1%) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta520) (any PD-L1 0% to 100%) or
* the [NICE technology appraisal guidance on nivolumab](https://www.nice.org.uk/guidance/ta655) (any PD-L1 0% to 100%) or
* docetaxel.

For people who have had initial treatment with platinum doublet chemotherapy and who have disease progression after treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428), [atezolizumab](https://www.nice.org.uk/guidance/ta520) or [nivolumab](https://www.nice.org.uk/guidance/ta655), the next recommended treatment option is docetaxel.

For people who have had treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428), [atezolizumab](https://www.nice.org.uk/guidance/ta520) or [nivolumab](https://www.nice.org.uk/guidance/ta655), and who have disease progression after follow-up treatment with docetaxel, recommended treatment options (available through the Cancer Drugs Fund) are:

* the [NICE technology appraisal guidance on entrectinib](https://www.nice.org.uk/guidance/ta644) or
* the [NICE technology appraisal guidance on larotrectinib](https://www.nice.org.uk/guidance/ta630).

For people who have had initial treatment with platinum doublet chemotherapy and who have disease progression after treatment with docetaxel, recommended treatment options are:

* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428) (if PD-L1 above 1%) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta520) (any PD-L1 0% to 100%) or
* the [NICE technology appraisal guidance on nivolumab](https://www.nice.org.uk/guidance/ta655) (any PD-L1 0% to 100%).

For people who have had treatment with docetaxel and who have disease progression after follow-up treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428), [atezolizumab](https://www.nice.org.uk/guidance/ta520) or [nivolumab](https://www.nice.org.uk/guidance/ta655), recommended treatment options (available through the Cancer Drugs Fund) are:

* the [NICE technology appraisal guidance on entrectinib](https://www.nice.org.uk/guidance/ta644) or
* the [NICE technology appraisal guidance on larotrectinib](https://www.nice.org.uk/guidance/ta630).

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab with carboplatin and paclitaxel](https://www.nice.org.uk/guidance/ta770), the next recommended treatment option is docetaxel.

For people who have had initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab with carboplatin and paclitaxel](https://www.nice.org.uk/guidance/ta770) and who have disease progression after follow-up treatment with docetaxel, recommended treatment options (available through the Cancer Drugs Fund) are:

* the [NICE technology appraisal guidance on entrectinib](https://www.nice.org.uk/guidance/ta644) or
* the [NICE technology appraisal guidance on larotrectinib](https://www.nice.org.uk/guidance/ta630).

## Squamous non-small cell lung cancer, NTRK fusion positive, PD‑L1 50% or higher

Initial recommended treatment options are:

* the [NICE technology appraisal guidance on pembrolizumab with carboplatin and paclitaxel](https://www.nice.org.uk/guidance/ta770) (only if urgent clinical intervention is needed) or
* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta531) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta705).

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab with carboplatin and paclitaxel](https://www.nice.org.uk/guidance/ta770), the next recommended treatment option is docetaxel.

For people who have had initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab with carboplatin and paclitaxel](https://www.nice.org.uk/guidance/ta770) and who have disease progression after treatment with docetaxel, recommended treatment options (available through the Cancer Drugs Fund) are:

* the [NICE technology appraisal guidance on entrectinib](https://www.nice.org.uk/guidance/ta644) or
* the [NICE technology appraisal guidance on larotrectinib](https://www.nice.org.uk/guidance/ta630).

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta531) or [atezolizumab](https://www.nice.org.uk/guidance/ta705), the next recommended treatment option is platinum doublet chemotherapy.

For people who have disease progression after platinum doublet chemotherapy, docetaxel is the next recommended treatment option.

For people who have had platinum doublet chemotherapy and who have disease progression after follow-up treatment with docetaxel, recommended treatment options (available through the Cancer Drugs Fund) are:

* the [NICE technology appraisal guidance on entrectinib](https://www.nice.org.uk/guidance/ta644) or
* the [NICE technology appraisal guidance on larotrectinib](https://www.nice.org.uk/guidance/ta630).

## Squamous non-small cell lung cancer, KRAS G12C positive, PD‑L1 below 50%

Initial recommended treatment options are:

* platinum doublet chemotherapy or
* the [NICE technology appraisal guidance on pembrolizumab with carboplatin and paclitaxel](https://www.nice.org.uk/guidance/ta770).

For people who have disease progression after initial treatment with platinum doublet chemotherapy, recommended treatment options are:

* the [NICE technology appraisal guidance on sotorasib](https://www.nice.org.uk/guidance/ta781) (available through the Cancer Drugs Fund) or
* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428) (if PD-L1 above 1%) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta520) (any PD-L1 0% to 100%) or
* the [NICE technology appraisal guidance on nivolumab](https://www.nice.org.uk/guidance/ta655) (any PD-L1 0% to 100%) or
* docetaxel.

For people who have had initial treatment with platinum doublet chemotherapy and who have disease progression after treatment in line with the [NICE technology appraisal guidance on sotorasib](https://www.nice.org.uk/guidance/ta781), recommended treatment options are:

* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428) (if PD-L1 above 1%) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta520) (any PD-L1 0% to 100%) or
* the [NICE technology appraisal guidance on nivolumab](https://www.nice.org.uk/guidance/ta655) (any PD-L1 0% to 100%) or
* docetaxel.

For people who have had treatment in line with the [NICE technology appraisal guidance on sotorasib](https://www.nice.org.uk/guidance/ta781) and who have disease progression after follow-up treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428), [atezolizumab](https://www.nice.org.uk/guidance/ta520) or [nivolumab](https://www.nice.org.uk/guidance/ta655), the only recommended treatment option is docetaxel (NHS England policy).

For people who have had treatment in line with the [NICE technology appraisal guidance on sotorasib](https://www.nice.org.uk/guidance/ta781) and who have disease progression after follow-up treatment with docetaxel, recommended treatment options (NHS England policy) are:

* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428) (if PD-L1 above 1%) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta520) (any PD-L1 0% to 100%) or
* the [NICE technology appraisal guidance on nivolumab](https://www.nice.org.uk/guidance/ta655) (any PD-L1 0% to 100%).

For people who have had initial treatment with platinum doublet chemotherapy and who have disease progression after treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428), [atezolizumab](https://www.nice.org.uk/guidance/ta520) or [nivolumab](https://www.nice.org.uk/guidance/ta655), recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on sotorasib](https://www.nice.org.uk/guidance/ta781) (available through the Cancer Drugs Fund).

For people who have had treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428), [atezolizumab](https://www.nice.org.uk/guidance/ta520) or [nivolumab](https://www.nice.org.uk/guidance/ta655), and who have disease progression after follow-up treatment with docetaxel, the only recommended treatment option is the [NICE technology appraisal guidance on sotorasib](https://www.nice.org.uk/guidance/ta781) (available through the Cancer Drugs Fund; NHS England policy).

For people who have had treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428), [atezolizumab](https://www.nice.org.uk/guidance/ta520) or [nivolumab](https://www.nice.org.uk/guidance/ta655), and who have disease progression after follow-up treatment in line with the [NICE technology appraisal guidance on sotorasib](https://www.nice.org.uk/guidance/ta781), the only recommended treatment option is docetaxel.

For people who have had initial treatment with platinum doublet chemotherapy and who have disease progression after treatment with docetaxel, recommended treatment options are:

* the [NICE technology appraisal guidance on sotorasib](https://www.nice.org.uk/guidance/ta781) (available through the Cancer Drugs Fund; NHS England policy) or
* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428) (if PD-L1 above 1%) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta520) (any PD-L1 0% to 100%) or
* the [NICE technology appraisal guidance on nivolumab](https://www.nice.org.uk/guidance/ta655) (any PD-L1 0% to 100%).

For people who have had treatment with docetaxel and who have disease progression after follow-up treatment in line with the [NICE technology appraisal guidance on sotorasib](https://www.nice.org.uk/guidance/ta781), recommended treatment options (NHS England policy) are:

* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428) (if PD-L1 above 1%) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta520) (any PD-L1 0% to 100%) or
* the [NICE technology appraisal guidance on nivolumab](https://www.nice.org.uk/guidance/ta655) (any PD-L1 0% to 100%).

For people who have had treatment with docetaxel and who have disease progression after follow-up treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428), [atezolizumab](https://www.nice.org.uk/guidance/ta520) or [nivolumab](https://www.nice.org.uk/guidance/ta655), the only recommended treatment option is the [NICE technology appraisal guidance on sotorasib](https://www.nice.org.uk/guidance/ta781) (available through the Cancer Drugs Fund).

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab with carboplatin and paclitaxel](https://www.nice.org.uk/guidance/ta770), recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on sotorasib](https://www.nice.org.uk/guidance/ta781) (available through the Cancer Drugs Fund).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab with carboplatin and paclitaxel](https://www.nice.org.uk/guidance/ta770), and who have disease progression after treatment with docetaxel, the only recommended treatment option is the [NICE technology appraisal guidance on sotorasib](https://www.nice.org.uk/guidance/ta781) (available through the Cancer Drugs Fund; NHS England policy).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab with carboplatin and paclitaxel](https://www.nice.org.uk/guidance/ta770), and who have disease progression after treatment in line with the [NICE technology appraisal guidance on sotorasib](https://www.nice.org.uk/guidance/ta781), the only recommended treatment option is docetaxel.

## Squamous non-small cell lung cancer, KRAS G12C positive, PD‑L1 50% or higher

Initial recommended treatment options are:

* the [NICE technology appraisal guidance on pembrolizumab with carboplatin and paclitaxel](https://www.nice.org.uk/guidance/ta770) (only if urgent clinical intervention is needed) or
* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta531) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta705).

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab with carboplatin and paclitaxel](https://www.nice.org.uk/guidance/ta770), recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on sotorasib](https://www.nice.org.uk/guidance/ta781) (available through the Cancer Drugs Fund).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab with carboplatin and paclitaxel](https://www.nice.org.uk/guidance/ta770) and who have disease progression after treatment with docetaxel, the only recommended treatment option is the [NICE technology appraisal guidance on sotorasib](https://www.nice.org.uk/guidance/ta781) (available through the Cancer Drugs Fund; NHS England policy).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab with carboplatin and paclitaxel](https://www.nice.org.uk/guidance/ta770) and who have disease progression after treatment in line with the [NICE technology appraisal guidance on sotorasib](https://www.nice.org.uk/guidance/ta781), the only recommended treatment option is docetaxel.

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta531) or [atezolizumab](https://www.nice.org.uk/guidance/ta705), recommended treatment options are:

* platinum doublet chemotherapy or
* the [NICE technology appraisal guidance on sotorasib](https://www.nice.org.uk/guidance/ta781) (available through the Cancer Drugs Fund).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta531) or [atezolizumab](https://www.nice.org.uk/guidance/ta705) and who have disease progression after treatment with platinum doublet chemotherapy, recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on sotorasib](https://www.nice.org.uk/guidance/ta781) (available through the Cancer Drugs Fund).

For people who have had platinum doublet chemotherapy and who have disease progression after follow-up treatment with docetaxel, the only recommended treatment option is the [NICE technology appraisal guidance on sotorasib](https://www.nice.org.uk/guidance/ta781) (available through the Cancer Drugs Fund; NHS England policy).

For people who have had platinum doublet chemotherapy and who have disease progression after follow-up treatment in line with the [NICE technology appraisal guidance on sotorasib](https://www.nice.org.uk/guidance/ta781), the only recommended treatment option is docetaxel.

For people who have had initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta531) or [atezolizumab](https://www.nice.org.uk/guidance/ta705) and who have disease progression after treatment in line with the [NICE technology appraisal guidance on sotorasib](https://www.nice.org.uk/guidance/ta781), recommended treatment options are:

* docetaxel or
* platinum doublet chemotherapy.

For people who have had treatment in line with the [NICE technology appraisal guidance on sotorasib](https://www.nice.org.uk/guidance/ta781) and who have disease progression after follow-up treatment with docetaxel, the only recommended treatment option is platinum doublet chemotherapy.

For people who have had treatment in line with the [NICE technology appraisal guidance on sotorasib](https://www.nice.org.uk/guidance/ta781) and who have disease progression after follow-up treatment with platinum doublet chemotherapy, the only recommended treatment option is docetaxel.

## Squamous non-small cell lung cancer, METex14 skipping alteration, PD‑L1 below 50%

Initial recommended treatment options are:

* platinum doublet chemotherapy or
* the [NICE technology appraisal guidance on pembrolizumab with carboplatin and paclitaxel](https://www.nice.org.uk/guidance/ta770) or
* the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789).

For people who have disease progression after initial treatment with platinum doublet chemotherapy, recommended treatment options are:

* the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789) or
* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428) (if PD-L1 above 1%) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta520) (any PD-L1 0% to 100%) or
* the [NICE technology appraisal guidance on nivolumab](https://www.nice.org.uk/guidance/ta655) (any PD-L1 0% to 100%) or
* docetaxel.

For people who have had initial treatment with platinum doublet chemotherapy and who have disease progression after treatment in line with the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789), recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428) (if PD-L1 above 1%) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta520) (any PD-L1 0% to 100%) or
* the [NICE technology appraisal guidance on nivolumab](https://www.nice.org.uk/guidance/ta655) (any PD-L1 0% to 100%)

For people who have had treatment in line with the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789) and who have disease progression after follow-up treatment with docetaxel, recommended treatment options (NHS England policy) are:

* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428) (if PD-L1 above 1%) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta520) (any PD-L1 0% to 100%) or
* the [NICE technology appraisal guidance on nivolumab](https://www.nice.org.uk/guidance/ta655) (any PD-L1 0% to 100%).

For people who have had treatment in line with the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789) and who have disease progression after follow-up treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428), [atezolizumab](https://www.nice.org.uk/guidance/ta520) or [nivolumab](https://www.nice.org.uk/guidance/ta655), the only recommended treatment option is docetaxel (NHS England policy).

For people who have had initial treatment with platinum doublet chemotherapy and who have disease progression after treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428), [atezolizumab](https://www.nice.org.uk/guidance/ta520) or [nivolumab](https://www.nice.org.uk/guidance/ta655), recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789).

For people who have had treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428), [atezolizumab](https://www.nice.org.uk/guidance/ta520) or [nivolumab](https://www.nice.org.uk/guidance/ta655), and who have disease progression after follow-up treatment with docetaxel, the only recommended treatment option is the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789).

For people who have had treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428), [atezolizumab](https://www.nice.org.uk/guidance/ta520) or [nivolumab](https://www.nice.org.uk/guidance/ta655), and who have disease progression after follow-up treatment in line with the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789), the only recommended treatment option is docetaxel.

For people who have had initial treatment with platinum doublet chemotherapy and who have disease progression after follow-up treatment with docetaxel, recommended treatment options are:

* the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789) or
* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428) (if PD-L1 above 1%) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta520) (any PD-L1 0% to 100%) or
* the [NICE technology appraisal guidance on nivolumab](https://www.nice.org.uk/guidance/ta655) (any PD-L1 0% to 100%).

For people who have had treatment with docetaxel and who have disease progression after follow-up treatment in line with the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789), recommended treatment options (NHS England policy) are:

* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428) (if PD-L1 above 1%) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta520) (any PD-L1 0% to 100%) or
* the [NICE technology appraisal guidance on nivolumab](https://www.nice.org.uk/guidance/ta655) (any PD-L1 0% to 100%).

For people who have had treatment with docetaxel and who have disease progression after follow-up treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428), [atezolizumab](https://www.nice.org.uk/guidance/ta520) or [nivolumab](https://www.nice.org.uk/guidance/ta655), the only recommended treatment option is the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789).

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab with carboplatin and paclitaxel](https://www.nice.org.uk/guidance/ta770), recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab with carboplatin and paclitaxel](https://www.nice.org.uk/guidance/ta770) and who have disease progression after treatment with docetaxel, the only recommended treatment option is the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab with carboplatin and paclitaxel](https://www.nice.org.uk/guidance/ta770) and who have disease progression after treatment in line with the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789), the only recommended treatment option is docetaxel.

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789), the only recommended treatment options is platinum doublet chemotherapy (NHS England policy).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789) and who have disease progression after platinum doublet chemotherapy, recommended treatment options are:

* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428) (if PD-L1 above 1%) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta520) (any PD-L1 0% to 100%) or
* the [NICE technology appraisal guidance on nivolumab](https://www.nice.org.uk/guidance/ta655) (any PD-L1 0% to 100%) or
* docetaxel (NHS England policy).

For people who have had platinum doublet chemotherapy and who have disease progression after follow-up treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428), [atezolizumab](https://www.nice.org.uk/guidance/ta520) or [nivolumab](https://www.nice.org.uk/guidance/ta655), the only recommended treatment option is docetaxel.

For people who have had platinum doublet chemotherapy and who have disease progression after follow-up treatment with docetaxel, recommended treatment options are:

* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428) (if PD-L1 above 1%) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta520) (any PD-L1 0% to 100%) or
* the [NICE technology appraisal guidance on nivolumab](https://www.nice.org.uk/guidance/ta655) (any PD-L1 0% to 100%).

## Squamous non-small cell lung cancer, METex14 skipping alteration, PD‑L1 50% or higher

Initial recommended treatment options are:

* the [NICE technology appraisal guidance on pembrolizumab with carboplatin and paclitaxel](https://www.nice.org.uk/guidance/ta770) (only if urgent clinical intervention is needed) or
* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta531) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta705) or
* the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789).

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab with carboplatin and paclitaxel](https://www.nice.org.uk/guidance/ta770), recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab with carboplatin and paclitaxel](https://www.nice.org.uk/guidance/ta770) and who have disease progression after treatment with docetaxel, the only recommended treatment option is the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab with carboplatin and paclitaxel](https://www.nice.org.uk/guidance/ta770) and who have disease progression after treatment in line with the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789), the only recommended treatment option is docetaxel.

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta531) or [atezolizumab](https://www.nice.org.uk/guidance/ta705), recommended treatment options are:

* platinum doublet chemotherapy or
* the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta531) or [atezolizumab](https://www.nice.org.uk/guidance/ta705) and who have disease progression after platinum doublet chemotherapy, recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789).

For people who have had platinum doublet chemotherapy and who have disease progression after follow-up treatment in line with the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789), the only recommended treatment option is docetaxel.

For people who have had initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta531) or [atezolizumab](https://www.nice.org.uk/guidance/ta705) and who have disease progression after treatment in line with the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789), recommended treatment options are:

* docetaxel or
* platinum doublet chemotherapy.

For people who have had treatment in line with the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789) and who have disease progression after follow-up treatment with docetaxel, the only recommended treatment option is platinum doublet chemotherapy.

For people who have had treatment in line with the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789) and who have disease progression after follow-up treatment with platinum doublet chemotherapy, the only recommended treatment option is docetaxel.

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789), the only recommended treatment option is platinum doublet chemotherapy (NHS England policy).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789) and who have disease progression after platinum doublet chemotherapy, recommended treatment options are:

* docetaxel (NHS England policy)
* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428) (if PD-L1 above 1%) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta520) (any PD-L1 0% to 100%) or
* the [NICE technology appraisal guidance on nivolumab](https://www.nice.org.uk/guidance/ta655) (any PD-L1 0% to 100%).

For people who have had platinum doublet chemotherapy and who have disease progression after follow-up treatment with docetaxel, recommended treatment options are:

* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428) (if PD-L1 above 1%) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta520) (any PD-L1 0% to 100%) or
* the [NICE technology appraisal guidance on nivolumab](https://www.nice.org.uk/guidance/ta655) (any PD-L1 0% to 100%).

For people who have had platinum doublet chemotherapy and who have disease progression after follow-up treatment in line with the [NICE technology appraisal guidance on pembrolizumab monotherapy](https://www.nice.org.uk/guidance/ta428), [atezolizumab](https://www.nice.org.uk/guidance/ta520) or [nivolumab](https://www.nice.org.uk/guidance/ta655), the only recommended treatment option is docetaxel.

## Squamous non-small cell lung cancer, BRAF V600 positive, PD‑L1 below 50%

Initial recommended treatment options are:

* platinum doublet chemotherapy or
* the [NICE technology appraisal guidance on pembrolizumab with carboplatin and paclitaxel](https://www.nice.org.uk/guidance/ta770) or
* the [NICE technology appraisal guidance on dabrafenib and trametinib](https://www.nice.org.uk/guidance/ta898).

For people who have disease progression after initial treatment with platinum doublet chemotherapy, recommended treatment options are:

* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428) (if PD-L1 above 1%) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta520) (any PD-L1 0% to 100%) or
* the [NICE technology appraisal guidance on nivolumab](https://www.nice.org.uk/guidance/ta655) (any PD-L1 0% to 100%) or
* docetaxel.

For people who have had initial treatment with platinum doublet chemotherapy and who have disease progression after treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta855), [atezolizumab](https://www.nice.org.uk/guidance/ta520) or [nivolumab](https://www.nice.org.uk/guidance/ta655), the only recommended treatment option is docetaxel.

For people who have had initial treatment with platinum doublet chemotherapy and who have disease progression after treatment with docetaxel, recommended treatment options are:

* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428) (if PD-L1 above 1%) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta520) (any PD-L1 0% to 100%) or
* the [NICE technology appraisal guidance on nivolumab](https://www.nice.org.uk/guidance/ta655) (any PD-L1 0% to 100%).

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab with carboplatin and paclitaxel](https://www.nice.org.uk/guidance/ta770), the only recommended treatment option is docetaxel.

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on dabrafenib and trametinib](https://www.nice.org.uk/guidance/ta898), the only recommended treatment option is platinum doublet chemotherapy (NHS England policy).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on dabrafenib and trametinib](https://www.nice.org.uk/guidance/ta898) and who have disease progression after treatment with platinum doublet chemotherapy, recommended treatment options are:

* docetaxel (NHS England policy) or
* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428) (if PD-L1 above 1%) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta520) (any PD-L1 0% to 100%) or
* the [NICE technology appraisal guidance on nivolumab](https://www.nice.org.uk/guidance/ta655) (any PD-L1 0% to 100%).

For people who have had treatment with platinum doublet chemotherapy and who have disease progression after follow-up treatment with docetaxel, recommended treatment options are:

* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428) (if PD-L1 above 1%) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta520) (any PD-L1 0% to 100%) or
* the [NICE technology appraisal guidance on nivolumab](https://www.nice.org.uk/guidance/ta655) (any PD-L1 0% to 100%).

For people who have had treatment with platinum doublet chemotherapy and who have disease progression after follow-up treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428), [atezolizumab](https://www.nice.org.uk/guidance/ta520) or [nivolumab](https://www.nice.org.uk/guidance/ta655), the only recommended treatment option is docetaxel.

## Squamous non-small cell lung cancer, BRAF V600 positive, PD‑L1 50% or higher

Initial recommended treatment options are:

* the [NICE technology appraisal guidance on pembrolizumab with carboplatin and paclitaxel](https://www.nice.org.uk/guidance/ta770) (only if urgent clinical intervention is needed) or
* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta531) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta705) or
* the [NICE technology appraisal guidance on dabrafenib and trametinib](https://www.nice.org.uk/guidance/ta898).

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab with carboplatin and paclitaxel](https://www.nice.org.uk/guidance/ta770), the only recommended treatment option is docetaxel.

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta531) or [atezolizumab](https://www.nice.org.uk/guidance/ta705), the only recommended treatment option is platinum doublet chemotherapy.

For people who have had initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta531) or [atezolizumab](https://www.nice.org.uk/guidance/ta705) and who have disease progression after treatment with platinum doublet chemotherapy, the only recommended treatment option is docetaxel.

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on dabrafenib and trametinib](https://www.nice.org.uk/guidance/ta898), the only recommended treatment option is platinum doublet chemotherapy (NHS England policy).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on dabrafenib and trametinib](https://www.nice.org.uk/guidance/ta898) and who have disease progression after treatment with platinum doublet chemotherapy, recommended treatment options are:

* docetaxel (NHS England policy) or
* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428) (if PD-L1 above 1%) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta520) (any PD-L1 0% to 100%) or
* the [NICE technology appraisal guidance on nivolumab](https://www.nice.org.uk/guidance/ta655) (any PD-L1 0% to 100%).

For people who have had treatment with platinum doublet chemotherapy and who have disease progression after follow-up treatment with docetaxel, recommended treatment options are:

* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428) (if PD-L1 above 1%) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta520) (any PD-L1 0% to 100%) or
* the [NICE technology appraisal guidance on nivolumab](https://www.nice.org.uk/guidance/ta655) (any PD-L1 0% to 100%).

For people who have had treatment with platinum doublet chemotherapy and who have disease progression after follow-up treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428), [atezolizumab](https://www.nice.org.uk/guidance/ta520) or [nivolumab](https://www.nice.org.uk/guidance/ta655), the only recommended treatment option is docetaxel.

## Non-squamous non-small cell lung cancer, no targetable mutations, PD‑L1 below 50%

Initial recommended treatment options are:

* platinum doublet chemotherapy or
* the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181) or
* pemetrexed and carboplatin or
* the [NICE technology appraisal guidance on atezolizumab and bevacizumab, carboplatin and paclitaxel](https://www.nice.org.uk/guidance/TA584) or
* the [NICE technology appraisal guidance on pembrolizumab and pemetrexed and platinum chemotherapy](https://www.nice.org.uk/guidance/ta683).

For maintenance treatment for people who have had initial treatment with platinum doublet chemotherapy, the only recommended treatment option is the [NICE technology appraisal guidance on pemetrexed maintenance](https://www.nice.org.uk/guidance/ta190).

For maintenance treatment for people who have had initial treatment in line with the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), the only recommended treatment option is the [NICE technology appraisal guidance on pemetrexed maintenance](https://www.nice.org.uk/guidance/ta402).

Pemetrexed maintenance is a recommended maintenance treatment option for people who have had initial treatment with pemetrexed and carboplatin (NHS England policy).

For people who have disease progression after initial treatment with platinum doublet chemotherapy, the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), pemetrexed and carboplatin, or after pemetrexed maintenance, recommended treatment options are:

* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428) (if PD‑l1 above 1%) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta520) (any PD-L1 0% to 100%) or
* the [NICE technology appraisal guidance on nivolumab](https://www.nice.org.uk/guidance/ta713) (if PD-L1 above 1%) or
* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347).

For people who have disease progression after treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428), [atezolizumab](https://www.nice.org.uk/guidance/ta520) or [nivolumab](https://www.nice.org.uk/guidance/ta713), recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on atezolizumab and bevacizumab, carboplatin and paclitaxel](https://www.nice.org.uk/guidance/TA584) or [pembrolizumab and pemetrexed and platinum chemotherapy](https://www.nice.org.uk/guidance/ta683), recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).

## Non-squamous non-small cell lung cancer, no targetable mutations, PD‑L1 50% or higher

Initial recommended treatment options are:

* the [NICE technology appraisal guidance on pembrolizumab and pemetrexed and platinum chemotherapy](https://www.nice.org.uk/guidance/ta683) or
* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta531) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta705).

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab and pemetrexed and platinum chemotherapy](https://www.nice.org.uk/guidance/ta683), recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta531) or [atezolizumab](https://www.nice.org.uk/guidance/ta705), recommended treatment options are:

* platinum doublet therapy or
* the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181) (NHS England policy) or
* pemetrexed and carboplatin.

For maintenance treatment for people who have had treatment with platinum doublet chemotherapy, the only recommended treatment option is the [NICE technology appraisal guidance on pemetrexed maintenance](https://www.nice.org.uk/guidance/ta190).

For maintenance treatment for people who have had treatment in line with the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), the only recommended treatment option is the [NICE technology appraisal guidance on pemetrexed maintenance](https://www.nice.org.uk/guidance/ta402).

Pemetrexed maintenance is a recommended maintenance treatment option for people who have had initial treatment with pemetrexed and carboplatin (NHS England policy).

For people who have disease progression after treatment with platinum doublet chemotherapy, the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), pemetrexed and carboplatin, or after pemetrexed maintenance, recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).

## Non-squamous non-small cell lung cancer, RET fusion positive, PD‑L1 below 50%

Initial recommended treatment options are:

* platinum doublet chemotherapy or
* the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181) or
* pemetrexed and carboplatin or
* the [NICE technology appraisal guidance on atezolizumab and bevacizumab, carboplatin and paclitaxel](https://www.nice.org.uk/guidance/TA584) or
* the [NICE technology appraisal guidance on pembrolizumab and pemetrexed and platinum chemotherapy](https://www.nice.org.uk/guidance/ta683) or
* the [NICE technology appraisal guidance on selpercatinib](https://www.nice.org.uk/guidance/indevelopment/gid-ta11012).

For maintenance treatment for people who have had initial treatment with platinum doublet chemotherapy, the only recommended treatment option is the [NICE technology appraisal guidance on pemetrexed maintenance](https://www.nice.org.uk/guidance/ta190).

For maintenance treatment for people who have had initial treatment in line with the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), the only recommended treatment option is the [NICE technology appraisal guidance on pemetrexed maintenance](https://www.nice.org.uk/guidance/ta402).

Pemetrexed maintenance is a recommended maintenance treatment option for people who have had initial treatment with pemetrexed and carboplatin (NHS England policy).

For people who have disease progression after initial treatment with platinum doublet chemotherapy, the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), pemetrexed and carboplatin, or who have had pemetrexed maintenance, recommended treatment options are:

* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428) (if PD‑L1 above 1%) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta520) (any PD-L1 0% to 100%) or
* the [NICE technology appraisal guidance on nivolumab](https://www.nice.org.uk/guidance/ta713) (if PD-L1 above 1%) or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) or
* docetaxel or
* the [NICE technology appraisal guidance on selpercatinib](https://www.nice.org.uk/guidance/ta760) (available through the Cancer Drugs Fund).

For people who have had initial treatment with platinum doublet chemotherapy, the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), pemetrexed and carboplatin, or who have had pemetrexed maintenance, and who have disease progression after treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428), [atezolizumab](https://www.nice.org.uk/guidance/ta520) or [nivolumab](https://www.nice.org.uk/guidance/ta713), recommended treatment options are:

* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy) or
* docetaxel or
* the [NICE technology appraisal guidance on selpercatinib](https://www.nice.org.uk/guidance/ta760) (available through the Cancer Drugs Fund).

For people who have had treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428), [atezolizumab](https://www.nice.org.uk/guidance/ta520) or [nivolumab](https://www.nice.org.uk/guidance/ta713), and who have disease progression after follow-up treatment in line with the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) or with docetaxel, the only recommended treatment option is the [NICE technology appraisal guidance on selpercatinib](https://www.nice.org.uk/guidance/ta760) (available through the Cancer Drugs Fund; NHS England policy).

For people who have had treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428), [atezolizumab](https://www.nice.org.uk/guidance/ta520) or [nivolumab](https://www.nice.org.uk/guidance/ta713), and who have disease progression after follow-up treatment in line with the [NICE technology appraisal guidance on selpercatinib](https://www.nice.org.uk/guidance/ta760), recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).

For people who have had initial treatment with platinum doublet chemotherapy, the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), pemetrexed and carboplatin, or who have had pemetrexed maintenance, and who have had disease progression after treatment in line with the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) or with docetaxel, the only recommended treatment option is the [NICE technology appraisal guidance on selpercatinib](https://www.nice.org.uk/guidance/ta760) (available through the Cancer Drugs Fund; NHS England policy).

For people who have had initial treatment with platinum doublet chemotherapy, the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), pemetrexed and carboplatin, or who have had pemetrexed maintenance, and who have had disease progression after treatment in line with the [NICE technology appraisal guidance on selpercatinib](https://www.nice.org.uk/guidance/ta760), recommended treatment options are:

* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428) (if PD‑L1 above 1%; NHS England policy) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta520) (any PD-L1 0% to 100%; NHS England policy) or
* the [NICE technology appraisal guidance on nivolumab](https://www.nice.org.uk/guidance/ta713) (if PD-L1 above 1%; NHS England policy) or
* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).

For people who have had treatment in line with the [NICE technology appraisal guidance on selpercatinib](https://www.nice.org.uk/guidance/ta760) and who have disease progression after follow-up treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428), [atezolizumab](https://www.nice.org.uk/guidance/ta520) or [nivolumab](https://www.nice.org.uk/guidance/ta713), recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on atezolizumab and bevacizumab, carboplatin and paclitaxel](https://www.nice.org.uk/guidance/TA584) or the [NICE technology appraisal guidance on pembrolizumab and pemetrexed and platinum chemotherapy](https://www.nice.org.uk/guidance/ta683), recommended treatment options are:

* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy) or
* docetaxel or
* the [NICE technology appraisal guidance on selpercatinib](https://www.nice.org.uk/guidance/ta760) (available through the Cancer Drugs Fund).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on atezolizumab and bevacizumab, carboplatin and paclitaxel](https://www.nice.org.uk/guidance/TA584) or [pembrolizumab and pemetrexed and platinum chemotherapy](https://www.nice.org.uk/guidance/ta683), and who have disease progression after treatment in line with the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) or with docetaxel, the only recommended treatment option is the [NICE technology appraisal guidance on selpercatinib](https://www.nice.org.uk/guidance/ta760) (available through the Cancer Drugs Fund; NHS England policy).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on atezolizumab and bevacizumab, carboplatin and paclitaxel](https://www.nice.org.uk/guidance/TA584) or [pembrolizumab and pemetrexed and platinum chemotherapy](https://www.nice.org.uk/guidance/ta683), and who have disease progression after treatment in line with the [NICE technology appraisal guidance on selpercatinib](https://www.nice.org.uk/guidance/ta760), recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on selpercatinib](https://www.nice.org.uk/guidance/indevelopment/gid-ta11012), recommended treatment options (NHS England policy) are:

* the [NICE technology appraisal guidance on atezolizumab and bevacizumab, carboplatin and paclitaxel](https://www.nice.org.uk/guidance/TA584) or
* platinum doublet chemotherapy or
* the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181) or
* pemetrexed and carboplatin.

For people who have had initial treatment in line with the [NICE technology appraisal guidance on selpercatinib](https://www.nice.org.uk/guidance/indevelopment/gid-ta11012) and who have disease progression after treatment in line with the [NICE technology appraisal guidance on atezolizumab and bevacizumab, carboplatin and paclitaxel](https://www.nice.org.uk/guidance/TA584), recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).

For maintenance treatment for people who have had initial treatment in line with the [NICE technology appraisal guidance on selpercatinib](https://www.nice.org.uk/guidance/indevelopment/gid-ta11012) followed by platinum doublet chemotherapy, the only recommended treatment option is the [NICE technology appraisal guidance on pemetrexed maintenance](https://www.nice.org.uk/guidance/ta190).

For maintenance treatment for people who have had initial treatment in line with the [NICE technology appraisal guidance on selpercatinib](https://www.nice.org.uk/guidance/indevelopment/gid-ta11012) followed by treatment in line with the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), the only recommended treatment option is the [NICE technology appraisal guidance on pemetrexed maintenance](https://www.nice.org.uk/guidance/ta402).

Pemetrexed maintenance is a recommended maintenance treatment option for people who have had initial treatment in line with the [NICE technology appraisal guidance on selpercatinib](https://www.nice.org.uk/guidance/indevelopment/gid-ta11012) followed by pemetrexed and carboplatin (NHS England policy).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on selpercatinib](https://www.nice.org.uk/guidance/indevelopment/gid-ta11012), and who have disease progression after platinum doublet chemotherapy, the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), pemetrexed and carboplatin, or who have had pemetrexed maintenance, recommended treatment options are:

* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428) (if PD‑L1 above 1%) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta520) (any PD-L1 0% to 100%) or
* the [NICE technology appraisal guidance on nivolumab](https://www.nice.org.uk/guidance/ta713) (if PD-L1 above 1%) or
* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).

For people who have had treatment with platinum doublet chemotherapy, the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), pemetrexed and carboplatin, or who have had pemetrexed maintenance, and have disease progression after follow-up treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428), [atezolizumab](https://www.nice.org.uk/guidance/ta520) or [nivolumab](https://www.nice.org.uk/guidance/ta713), recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).

## Non-squamous non-small cell lung cancer, RET fusion positive, PD‑L1 50% or higher

Initial recommended treatment options are:

* the [NICE technology appraisal guidance on pembrolizumab and pemetrexed and platinum chemotherapy](https://www.nice.org.uk/guidance/ta683) or
* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta531) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta705) or
* the [NICE technology appraisal guidance on selpercatinib](https://www.nice.org.uk/guidance/indevelopment/gid-ta11012).

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab and pemetrexed and platinum chemotherapy](https://www.nice.org.uk/guidance/ta683), recommended treatment options are:

* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy) or
* docetaxel or
* the [NICE technology appraisal guidance on selpercatinib](https://www.nice.org.uk/guidance/ta760) (available through the Cancer Drugs Fund).

For people who have had treatment in line with the [NICE technology appraisal guidance on pembrolizumab and pemetrexed and platinum chemotherapy](https://www.nice.org.uk/guidance/ta683), and who have had disease progression after treatment in line with the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) or with docetaxel, the only recommended treatment option is the [NICE technology appraisal guidance on selpercatinib](https://www.nice.org.uk/guidance/ta760) (available through the Cancer Drugs Fund; NHS England policy).

For people who have had treatment in line with the [NICE technology appraisal guidance on pembrolizumab and pemetrexed and platinum chemotherapy](https://www.nice.org.uk/guidance/ta683), and who have had disease progression after treatment in line with the [NICE technology appraisal guidance on selpercatinib](https://www.nice.org.uk/guidance/ta760), recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta531) or [atezolizumab](https://www.nice.org.uk/guidance/ta705), recommended treatment options are:

* platinum doublet therapy (NHS England policy) or
* the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181) (NHS England policy) or
* pemetrexed and carboplatin (NHS England policy) or
* the [NICE technology appraisal guidance on selpercatinib](https://www.nice.org.uk/guidance/ta760) (available through the Cancer Drugs Fund).

For maintenance treatment for people who have had treatment with platinum doublet chemotherapy, the only recommended treatment option is the [NICE technology appraisal guidance on pemetrexed maintenance](https://www.nice.org.uk/guidance/ta190).

For maintenance treatment for people who have had treatment in line with the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), the only recommended treatment option is the [NICE technology appraisal guidance on pemetrexed maintenance](https://www.nice.org.uk/guidance/ta402).

Pemetrexed maintenance is a recommended maintenance treatment option for people who have had initial treatment with pemetrexed and carboplatin (NHS England policy).

For people who have disease progression after treatment with platinum doublet chemotherapy, the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), pemetrexed and carboplatin, or after pemetrexed maintenance, recommended treatment options are:

* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy) or
* docetaxel or
* the [NICE technology appraisal guidance on selpercatinib](https://www.nice.org.uk/guidance/ta760) (available through the Cancer Drugs Fund).

For people who have had treatment with platinum doublet chemotherapy, the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), pemetrexed and carboplatin, or who have had pemetrexed maintenance, and who have had disease progression after treatment in line with the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) or with docetaxel, the only recommended treatment option is the [NICE technology appraisal guidance on selpercatinib](https://www.nice.org.uk/guidance/ta760) (available through the Cancer Drugs Fund; NHS England policy).

For people who have had treatment with platinum doublet chemotherapy, the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), pemetrexed and carboplatin, or who have had pemetrexed maintenance, and who have had disease progression after treatment in line with the [NICE technology appraisal guidance on selpercatinib](https://www.nice.org.uk/guidance/ta760), recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta531) or [atezolizumab](https://www.nice.org.uk/guidance/ta705) and who have disease progression after treatment in line with the [NICE technology appraisal guidance on selpercatinib](https://www.nice.org.uk/guidance/ta760), the only recommended treatment option is docetaxel.

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on selpercatinib](https://www.nice.org.uk/guidance/indevelopment/gid-ta11012), recommended treatment options (NHS England policy) are:

* the [NICE technology appraisal guidance on atezolizumab and bevacizumab, carboplatin and paclitaxel](https://www.nice.org.uk/guidance/TA584) or
* platinum doublet chemotherapy or
* the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181) or
* pemetrexed and carboplatin.

For people who have had initial treatment in line with the [NICE technology appraisal guidance on selpercatinib](https://www.nice.org.uk/guidance/indevelopment/gid-ta11012) and who have disease progression after treatment in line with the [NICE technology appraisal guidance on atezolizumab and bevacizumab, carboplatin and paclitaxel](https://www.nice.org.uk/guidance/TA584), recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).

For maintenance treatment for people who have had initial treatment in line with the [NICE technology appraisal guidance on selpercatinib](https://www.nice.org.uk/guidance/indevelopment/gid-ta11012) followed by platinum doublet chemotherapy, the only recommended treatment option is the [NICE technology appraisal guidance on pemetrexed maintenance](https://www.nice.org.uk/guidance/ta190).

For maintenance treatment for people who have had initial treatment in line with the [NICE technology appraisal guidance on selpercatinib](https://www.nice.org.uk/guidance/indevelopment/gid-ta11012) followed by treatment in line with the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), the only recommended treatment option is the [NICE technology appraisal guidance on pemetrexed maintenance](https://www.nice.org.uk/guidance/ta402).

Pemetrexed maintenance is a recommended maintenance treatment option for people who have had initial treatment in line with the [NICE technology appraisal guidance on selpercatinib](https://www.nice.org.uk/guidance/indevelopment/gid-ta11012) followed by pemetrexed and carboplatin (NHS England policy).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on selpercatinib](https://www.nice.org.uk/guidance/indevelopment/gid-ta11012), and who have disease progression after platinum doublet chemotherapy, the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), pemetrexed and carboplatin, or who have had pemetrexed maintenance, recommended treatment options are:

* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428) (if PD‑L1 above 1%) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta520) (any PD-L1 0% to 100%) or
* the [NICE technology appraisal guidance on nivolumab](https://www.nice.org.uk/guidance/ta713) (if PD-L1 above 1%) or
* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).

For people who have had treatment with platinum doublet chemotherapy, the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), pemetrexed and carboplatin, or who have had pemetrexed maintenance, and have disease progression after follow-up treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428), [atezolizumab](https://www.nice.org.uk/guidance/ta520) or [nivolumab](https://www.nice.org.uk/guidance/ta713), recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).

## Non-squamous non-small cell lung cancer, NTRK fusion positive, PD‑L1 below 50%

Initial recommended treatment options are:

* platinum doublet chemotherapy or
* the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181) or
* pemetrexed and carboplatin or
* the [NICE technology appraisal guidance on atezolizumab and bevacizumab, carboplatin and paclitaxel](https://www.nice.org.uk/guidance/TA584) or
* the [NICE technology appraisal guidance on pembrolizumab and pemetrexed and platinum chemotherapy](https://www.nice.org.uk/guidance/ta683).

For maintenance treatment for people who have had initial treatment with platinum doublet chemotherapy, the only recommended treatment option is the [NICE technology appraisal guidance on pemetrexed maintenance](https://www.nice.org.uk/guidance/ta190).

For maintenance treatment for people who have had initial treatment in line with the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), the only recommended treatment option is the [NICE technology appraisal guidance on pemetrexed maintenance](https://www.nice.org.uk/guidance/ta402).

Pemetrexed maintenance is a recommended maintenance treatment option for people who have had initial treatment with pemetrexed and carboplatin (NHS England policy).

For people who have disease progression after initial treatment with platinum doublet chemotherapy, the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), pemetrexed and carboplatin, or after pemetrexed maintenance, recommended treatment options are:

* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428) (if PD‑L1 above 1%) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta520) (any PD-L1 0% to 100%) or
* the [NICE technology appraisal guidance on nivolumab](https://www.nice.org.uk/guidance/ta713) (if PD-L1 above 1%) or
* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347).

For people who have had initial treatment with platinum doublet chemotherapy, the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), pemetrexed and carboplatin, or who have had pemetrexed maintenance, and who have disease progression after treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428), [atezolizumab](https://www.nice.org.uk/guidance/ta520) or [nivolumab](https://www.nice.org.uk/guidance/ta713), recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).

For people who have had treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428), [atezolizumab](https://www.nice.org.uk/guidance/ta520) or [nivolumab](https://www.nice.org.uk/guidance/ta713), and who have disease progression after follow-up treatment with docetaxel or in line with the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347), recommended treatment options (available through the Cancer Drugs Fund) are:

* the [NICE technology appraisal guidance on entrectinib](https://www.nice.org.uk/guidance/ta644) or
* the [NICE technology appraisal guidance on larotrectinib](https://www.nice.org.uk/guidance/ta630).

For people who have had initial treatment with platinum doublet chemotherapy, the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), pemetrexed and carboplatin, or who have had pemetrexed maintenance, and who have disease progression after treatment with docetaxel or in line with the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347), recommended treatment options (available through the Cancer Drugs Fund) are:

* the [NICE technology appraisal guidance on entrectinib](https://www.nice.org.uk/guidance/ta644) or
* the [NICE technology appraisal guidance on larotrectinib](https://www.nice.org.uk/guidance/ta630).

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on atezolizumab and bevacizumab, carboplatin and paclitaxel](https://www.nice.org.uk/guidance/TA584) or [pembrolizumab and pemetrexed and platinum chemotherapy](https://www.nice.org.uk/guidance/ta683), recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on atezolizumab and bevacizumab, carboplatin and paclitaxel](https://www.nice.org.uk/guidance/TA584) or [pembrolizumab and pemetrexed and platinum chemotherapy](https://www.nice.org.uk/guidance/ta683), and who have disease progression after follow-up treatment with docetaxel or in line with the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347), recommended treatment options (available through the Cancer Drugs Fund) are:

* the [NICE technology appraisal guidance on entrectinib](https://www.nice.org.uk/guidance/ta644) or
* the [NICE technology appraisal guidance on larotrectinib](https://www.nice.org.uk/guidance/ta630).

## Non-squamous non-small cell lung cancer, NTRK fusion positive, PD‑L1 50% or higher

Initial recommended treatment options are:

* the [NICE technology appraisal guidance on pembrolizumab and pemetrexed and platinum chemotherapy](https://www.nice.org.uk/guidance/ta683) or
* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta531) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta705).

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab and pemetrexed and platinum chemotherapy](https://www.nice.org.uk/guidance/ta683), recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab and pemetrexed and platinum chemotherapy](https://www.nice.org.uk/guidance/ta683), and who have disease progression after follow-up treatment with docetaxel or in line with the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347), recommended treatment options (available through the Cancer Drugs Fund) are:

* the [NICE technology appraisal guidance on entrectinib](https://www.nice.org.uk/guidance/ta644) or
* the [NICE technology appraisal guidance on larotrectinib](https://www.nice.org.uk/guidance/ta630).

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta531) or [atezolizumab](https://www.nice.org.uk/guidance/ta705), recommended treatment options (NHS England policy) are:

* platinum doublet therapy or
* the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181) or
* pemetrexed and carboplatin.

For maintenance treatment for people who have had treatment with platinum doublet chemotherapy, the only recommended treatment option is the [NICE technology appraisal guidance on pemetrexed maintenance](https://www.nice.org.uk/guidance/ta190).

For maintenance treatment for people who have had treatment in line with the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), the only recommended treatment option is the [NICE technology appraisal guidance on pemetrexed maintenance](https://www.nice.org.uk/guidance/ta402).

Pemetrexed maintenance is a recommended maintenance treatment option for people who have had treatment with pemetrexed and carboplatin (NHS England policy).

For people who have disease progression after treatment with platinum doublet chemotherapy, the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), pemetrexed and carboplatin, or after pemetrexed maintenance, recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).

For people who have had treatment with platinum doublet chemotherapy, the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), pemetrexed and carboplatin, or after pemetrexed maintenance, and who have disease progression after follow-up treatment with docetaxel or in line with the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347), recommended treatment options (available through the Cancer Drugs Fund) are:

* the [NICE technology appraisal guidance on entrectinib](https://www.nice.org.uk/guidance/ta644) or
* the [NICE technology appraisal guidance on larotrectinib](https://www.nice.org.uk/guidance/ta630).

## Non-squamous non-small cell lung cancer, KRAS G12C positive, PD‑L1 below 50%

Initial recommended treatment options are:

* platinum doublet chemotherapy or
* the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181) or
* pemetrexed and carboplatin or
* the [NICE technology appraisal guidance on atezolizumab and bevacizumab, carboplatin and paclitaxel](https://www.nice.org.uk/guidance/TA584) or
* the [NICE technology appraisal guidance on pembrolizumab and pemetrexed and platinum chemotherapy](https://www.nice.org.uk/guidance/ta683).

For maintenance treatment for people who have had initial treatment with platinum doublet chemotherapy, the only recommended treatment option is the [NICE technology appraisal guidance on pemetrexed maintenance](https://www.nice.org.uk/guidance/ta190).

For maintenance treatment for people who have had initial treatment in line with the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), the only recommended treatment option is the [NICE technology appraisal guidance on pemetrexed maintenance](https://www.nice.org.uk/guidance/ta402).

Pemetrexed maintenance is a recommended maintenance treatment option for people who have had initial treatment with pemetrexed and carboplatin (NHS England policy).

For people who have disease progression after initial treatment with platinum doublet chemotherapy, the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), pemetrexed and carboplatin, or who have had pemetrexed maintenance, recommended treatment options are:

* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428) (if PD‑L1 above 1%) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta520) (any PD-L1 0% to 100%) or
* the [NICE technology appraisal guidance on nivolumab](https://www.nice.org.uk/guidance/ta713) (if PD-L1 above 1%) or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) or
* docetaxel or
* the [NICE technology appraisal guidance on sotorasib](https://www.nice.org.uk/guidance/ta781) (available through the Cancer Drugs Fund).

For people who have had initial treatment with platinum doublet chemotherapy, the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), pemetrexed and carboplatin, or who have had pemetrexed maintenance, and who have had disease progression after treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428), [atezolizumab](https://www.nice.org.uk/guidance/ta520) or [nivolumab](https://www.nice.org.uk/guidance/ta713), recommended treatment options are:

* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy) or
* docetaxel or
* the [NICE technology appraisal guidance on sotorasib](https://www.nice.org.uk/guidance/ta781) (available through the Cancer Drugs Fund).

For people who have had treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428), [atezolizumab](https://www.nice.org.uk/guidance/ta520) or [nivolumab](https://www.nice.org.uk/guidance/ta713), and who have disease progression after follow-up treatment in line with the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) or with docetaxel, the only recommended treatment option is the [NICE technology appraisal guidance on sotorasib](https://www.nice.org.uk/guidance/ta781) (available through the Cancer Drugs Fund; NHS England policy).

For people who have had treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428), [atezolizumab](https://www.nice.org.uk/guidance/ta520) or [nivolumab](https://www.nice.org.uk/guidance/ta713), and who have disease progression after follow-up treatment in line with the [NICE technology appraisal guidance on sotorasib](https://www.nice.org.uk/guidance/ta781), recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).

For people who have had initial treatment with platinum doublet chemotherapy, the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), pemetrexed and carboplatin, or who have had pemetrexed maintenance, and who have had disease progression after treatment in line with the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) or with docetaxel, the only recommended treatment option is the [NICE technology appraisal guidance on sotorasib](https://www.nice.org.uk/guidance/ta781) (available through the Cancer Drugs Fund; NHS England policy).

For people who have had initial treatment with platinum doublet chemotherapy, the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), pemetrexed and carboplatin, or who have had pemetrexed maintenance, and who have had disease progression after treatment in line with the [NICE technology appraisal guidance on selpercatinib](https://www.nice.org.uk/guidance/ta760), recommended treatment options are:

* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428) (if PD‑L1 above 1%; NHS England policy) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta520) (any PD-L1 0% to 100%; NHS England policy) or
* the [NICE technology appraisal guidance on nivolumab](https://www.nice.org.uk/guidance/ta713) (if PD-L1 above 1%; NHS England policy) or
* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).

For people who have had treatment in line with the [NICE technology appraisal guidance on selpercatinib](https://www.nice.org.uk/guidance/ta760) and who have disease progression after follow-up treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428), [atezolizumab](https://www.nice.org.uk/guidance/ta520) or [nivolumab](https://www.nice.org.uk/guidance/ta713), recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on atezolizumab and bevacizumab, carboplatin and paclitaxel](https://www.nice.org.uk/guidance/TA584) or [pembrolizumab and pemetrexed and platinum chemotherapy](https://www.nice.org.uk/guidance/ta683), recommended treatment options are:

* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy) or
* docetaxel or
* the [NICE technology appraisal guidance on sotorasib](https://www.nice.org.uk/guidance/ta781) (available through the Cancer Drugs Fund).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on atezolizumab and bevacizumab, carboplatin and paclitaxel](https://www.nice.org.uk/guidance/TA584) or [pembrolizumab and pemetrexed and platinum chemotherapy](https://www.nice.org.uk/guidance/ta683), and who have had disease progression after treatment in line with the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) or with docetaxel, the only recommended treatment option is the [NICE technology appraisal guidance on sotorasib](https://www.nice.org.uk/guidance/ta781) (available through the Cancer Drugs Fund; NHS England policy).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on atezolizumab and bevacizumab, carboplatin and paclitaxel](https://www.nice.org.uk/guidance/TA584) or [pembrolizumab and pemetrexed and platinum chemotherapy](https://www.nice.org.uk/guidance/ta683), and who have had disease progression after treatment in line with the [NICE technology appraisal guidance on sotorasib](https://www.nice.org.uk/guidance/ta781), recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).

## Non-squamous non-small cell lung cancer, KRAS G12C fusion positive, PD‑L1 50% or higher

Initial recommended treatment options are:

* the [NICE technology appraisal guidance on pembrolizumab and pemetrexed and platinum chemotherapy](https://www.nice.org.uk/guidance/ta683) or
* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta531) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta705).

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab and pemetrexed and platinum chemotherapy](https://www.nice.org.uk/guidance/ta683), recommended treatment options are:

* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy) or
* docetaxel or
* the [NICE technology appraisal guidance on sotorasib](https://www.nice.org.uk/guidance/ta781) (available through the Cancer Drugs Fund).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab and pemetrexed and platinum chemotherapy](https://www.nice.org.uk/guidance/ta683) and who have disease progression after treatment in line with the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) or with docetaxel, the only recommended treatment option is the [NICE technology appraisal guidance on sotorasib](https://www.nice.org.uk/guidance/ta781) (available through the Cancer Drugs Fund; NHS England policy).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab and pemetrexed and platinum chemotherapy](https://www.nice.org.uk/guidance/ta683) and who have disease progression after treatment in line with the [NICE technology appraisal guidance on sotorasib](https://www.nice.org.uk/guidance/ta781), recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta531) or [atezolizumab](https://www.nice.org.uk/guidance/ta705), recommended treatment options are:

* platinum doublet therapy (NHS England policy) or
* the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181) (NHS England policy) or
* pemetrexed and carboplatin (NHS England policy) or
* the [NICE technology appraisal guidance on sotorasib](https://www.nice.org.uk/guidance/ta781) (available through the Cancer Drugs Fund).

For maintenance treatment for people who have had treatment with platinum doublet chemotherapy, the only recommended treatment option is the [NICE technology appraisal guidance on pemetrexed maintenance](https://www.nice.org.uk/guidance/ta190).

For maintenance treatment for people who have had treatment in line with the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), the only recommended treatment option is the [NICE technology appraisal guidance on pemetrexed maintenance](https://www.nice.org.uk/guidance/ta402).

Pemetrexed maintenance is a recommended maintenance treatment option for people who have had initial treatment with pemetrexed and carboplatin (NHS England policy).

For people who have disease progression after treatment with platinum doublet chemotherapy, the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), pemetrexed and carboplatin, or after pemetrexed maintenance, recommended treatment options are:

* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy) or
* docetaxel or
* the [NICE technology appraisal guidance on sotorasib](https://www.nice.org.uk/guidance/ta781) (available through the Cancer Drugs Fund).

For people who have had treatment with platinum doublet chemotherapy, the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), pemetrexed and carboplatin, or who have had pemetrexed maintenance, and who have had disease progression after follow-up treatment in line with the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) or with docetaxel, the only recommended treatment option is the [NICE technology appraisal guidance on sotorasib](https://www.nice.org.uk/guidance/ta781) (available through the Cancer Drugs Fund; NHS England policy).

For people who have had treatment with platinum doublet chemotherapy, the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), pemetrexed and carboplatin, or who have had pemetrexed maintenance, and who have had disease progression after follow-up treatment in line with the [NICE technology appraisal guidance on sotorasib](https://www.nice.org.uk/guidance/ta781), recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta531) or [atezolizumab](https://www.nice.org.uk/guidance/ta705) and who have disease progression after treatment in line with the [NICE technology appraisal guidance on sotorasib](https://www.nice.org.uk/guidance/ta781), the only recommended treatment option is docetaxel.

## Non-squamous non-small cell lung cancer, METex14 skipping alteration, PD‑L1 below 50%

Initial recommended treatment options are:

* platinum doublet chemotherapy or
* the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181) or
* pemetrexed and carboplatin or
* the [NICE technology appraisal guidance on atezolizumab and bevacizumab, carboplatin and paclitaxel](https://www.nice.org.uk/guidance/TA584) or
* the [NICE technology appraisal guidance on pembrolizumab and pemetrexed and platinum chemotherapy](https://www.nice.org.uk/guidance/ta683) or
* the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789).

For maintenance treatment for people who have had initial treatment with platinum doublet chemotherapy, the only recommended treatment option is the [NICE technology appraisal guidance on pemetrexed maintenance](https://www.nice.org.uk/guidance/ta190).

For maintenance treatment for people who have had initial treatment in line with the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), the only recommended treatment option is the [NICE technology appraisal guidance on pemetrexed maintenance](https://www.nice.org.uk/guidance/ta402).

Pemetrexed maintenance is a recommended maintenance treatment option for people who have had initial treatment with pemetrexed and carboplatin (NHS England policy).

For people who have disease progression after initial treatment with platinum doublet chemotherapy, the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), pemetrexed and carboplatin, or who have had pemetrexed maintenance, recommended treatment options are:

* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428) (if PD‑L1 above 1%) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta520) (any PD-L1 0% to 100%) or
* the [NICE technology appraisal guidance on nivolumab](https://www.nice.org.uk/guidance/ta713) (if PD-L1 above 1%) or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) or
* docetaxel or
* the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789).

For people who have had initial treatment with platinum doublet chemotherapy, the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), pemetrexed and carboplatin, or who have had pemetrexed maintenance, and who have disease progression after follow-up treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428), [atezolizumab](https://www.nice.org.uk/guidance/ta520) or [nivolumab](https://www.nice.org.uk/guidance/ta713), recommended treatment options are:

* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy) or
* docetaxel or
* the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789).

For people who have had treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428), [atezolizumab](https://www.nice.org.uk/guidance/ta520) or [nivolumab](https://www.nice.org.uk/guidance/ta713), and who have disease progression after follow-up treatment in line with the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) or with docetaxel, the only recommended treatment option is the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789).

For people who have had treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428), [atezolizumab](https://www.nice.org.uk/guidance/ta520) or [nivolumab](https://www.nice.org.uk/guidance/ta713), and who have disease progression after follow-up treatment in line with the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789), recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).

For people who have had initial treatment with platinum doublet chemotherapy, the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), pemetrexed and carboplatin, or who have had pemetrexed maintenance, and who have disease progression after treatment in line with the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) or docetaxel, the only recommended treatment option is the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789).

For people who have had initial treatment with platinum doublet chemotherapy, the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), pemetrexed and carboplatin, or who have had pemetrexed maintenance, and who have disease progression after treatment in line with the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789), recommended treatment options are:

* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428) (if PD‑L1 above 1%; NHS England policy) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta520) (any PD-L1 0% to 100%; NHS England policy) or
* the [NICE technology appraisal guidance on nivolumab](https://www.nice.org.uk/guidance/ta713) (if PD-L1 above 1%; NHS England policy) or
* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).

For people who have had treatment in line with the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789) and who have disease progression after follow-up treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428), [atezolizumab](https://www.nice.org.uk/guidance/ta520), or [nivolumab](https://www.nice.org.uk/guidance/ta713), recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on atezolizumab and bevacizumab, carboplatin and paclitaxel](https://www.nice.org.uk/guidance/TA584) or [pembrolizumab and pemetrexed and platinum chemotherapy](https://www.nice.org.uk/guidance/ta683), recommended treatment options are:

* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy) or
* docetaxel or
* the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on atezolizumab and bevacizumab, carboplatin and paclitaxel](https://www.nice.org.uk/guidance/TA584) or [pembrolizumab and pemetrexed and platinum chemotherapy](https://www.nice.org.uk/guidance/ta683), and who have disease progression after treatment in line with the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) or with docetaxel, the only recommended treatment option is the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on atezolizumab and bevacizumab, carboplatin and paclitaxel](https://www.nice.org.uk/guidance/TA584) or [pembrolizumab and pemetrexed and platinum chemotherapy](https://www.nice.org.uk/guidance/ta683), and who have disease progression after treatment in line with the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789), recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789), recommended treatment options (NHS England policy) are:

* the [NICE technology appraisal guidance on atezolizumab and bevacizumab, carboplatin and paclitaxel](https://www.nice.org.uk/guidance/TA584) or
* platinum doublet chemotherapy or
* the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181) or
* pemetrexed and carboplatin.

For people who have had initial treatment in line with the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789) and who have disease progression after treatment in line with the [NICE technology appraisal guidance on atezolizumab and bevacizumab, carboplatin and paclitaxel](https://www.nice.org.uk/guidance/TA584), recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).

For maintenance treatment for people who have had initial treatment in line with the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789) followed by treatment with platinum doublet chemotherapy, the only recommended treatment option is the [NICE technology appraisal guidance on pemetrexed maintenance](https://www.nice.org.uk/guidance/ta190).

For maintenance treatment for people who have had initial treatment in line with the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789) followed by treatment in line with the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), the only recommended treatment option is the [NICE technology appraisal guidance on pemetrexed maintenance](https://www.nice.org.uk/guidance/ta402).

Pemetrexed maintenance is a recommended maintenance treatment option for people who have had initial treatment in line with the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789) followed by treatment with pemetrexed and carboplatin (NHS England policy).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789) and who have disease progression after treatment with platinum doublet chemotherapy, the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), pemetrexed and carboplatin, or pemetrexed maintenance, recommended treatment options are:

* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428) (if PD‑L1 above 1%) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta520) (any PD-L1 0% to 100%) or
* the [NICE technology appraisal guidance on nivolumab](https://www.nice.org.uk/guidance/ta713) (if PD-L1 above 1%) or
* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).

For people who have had treatment with platinum doublet chemotherapy, the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), pemetrexed and carboplatin, or pemetrexed maintenance, and who have disease progression after follow-up treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428), [atezolizumab](https://www.nice.org.uk/guidance/ta520) or [nivolumab](https://www.nice.org.uk/guidance/ta713), recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).

## Non-squamous non-small cell lung cancer, METex14 skipping alteration, PD‑L1 50% or higher

Initial recommended treatment options are:

* the [NICE technology appraisal guidance on pembrolizumab and pemetrexed and platinum chemotherapy](https://www.nice.org.uk/guidance/ta683) or
* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta531) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta705) or
* the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789).

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab and pemetrexed and platinum chemotherapy](https://www.nice.org.uk/guidance/ta683), recommended treatment options are:

* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy) or
* docetaxel or
* the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab and pemetrexed and platinum chemotherapy](https://www.nice.org.uk/guidance/ta683) and who have disease progression after treatment in line with the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) or with docetaxel, the only recommended treatment option is the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab and pemetrexed and platinum chemotherapy](https://www.nice.org.uk/guidance/ta683) and who have disease progression after follow-up treatment in line with the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789), recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta531) or [atezolizumab](https://www.nice.org.uk/guidance/ta705), recommended treatment options are:

* platinum doublet therapy (NHS England policy) or
* the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/ta181) (NHS England policy) or
* pemetrexed and carboplatin (NHS England policy) or
* the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789).

For maintenance treatment for people who have had treatment with platinum doublet chemotherapy, the only recommended treatment option is the [NICE technology appraisal guidance on pemetrexed maintenance](https://www.nice.org.uk/guidance/ta190).

For maintenance treatment for people who have had treatment in line with the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/ta181), the only recommended treatment option is the [NICE technology appraisal guidance on pemetrexed maintenance](https://www.nice.org.uk/guidance/ta402).

Pemetrexed maintenance is a recommended maintenance treatment option for people who have had initial treatment with pemetrexed and carboplatin (NHS England policy).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta531) or [atezolizumab](https://www.nice.org.uk/guidance/ta705), and who have disease progression after treatment with platinum doublet chemotherapy, the [NICE technology appraisal guidance on pemetrexed](https://www.nice.org.uk/guidance/ta181), pemetrexed and carboplatin, or after pemetrexed maintenance, recommended treatment options are:

* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy) or
* docetaxel or
* the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789).

For people who have had treatment with platinum doublet chemotherapy, the [NICE technology appraisal guidance on pemetrexed](https://www.nice.org.uk/guidance/ta181), pemetrexed and carboplatin, or who have had pemetrexed maintenance, and who have had disease progression after follow-up treatment in line with the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) or with docetaxel, the only recommended treatment option is the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789).

For people who have had initial treatment with platinum doublet chemotherapy, the [NICE technology appraisal guidance on pemetrexed](https://www.nice.org.uk/guidance/ta181), pemetrexed and carboplatin, or who have had pemetrexed maintenance, and who have disease progression after follow-up treatment in line with the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789), recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta531) or [atezolizumab](https://www.nice.org.uk/guidance/ta705), and who have disease progression after treatment in line with the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789), the only recommended treatment option is docetaxel.

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789), recommended treatment options (NHS England policy) are:

* the [NICE technology appraisal guidance on atezolizumab and bevacizumab, carboplatin and paclitaxel](https://www.nice.org.uk/guidance/TA584) or
* platinum doublet therapy or
* the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181) or
* pemetrexed and carboplatin.

For people who have disease progression after treatment in line with the [NICE technology appraisal guidance on atezolizumab and bevacizumab, carboplatin and paclitaxel](https://www.nice.org.uk/guidance/TA584), recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).

For maintenance treatment for people who have had treatment in line with the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789), followed by platinum doublet chemotherapy, the only recommended treatment option is the [NICE technology appraisal guidance on pemetrexed maintenance](https://www.nice.org.uk/guidance/ta190).

For maintenance treatment for people who have had treatment in line with the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789), followed by treatment in line with the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), the only recommended treatment option is the [NICE technology appraisal guidance on pemetrexed maintenance](https://www.nice.org.uk/guidance/ta402).

Pemetrexed maintenance is a recommended maintenance treatment option for people who have had initial treatment in line with the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789), followed by pemetrexed and carboplatin (NHS England policy).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on tepotinib](https://www.nice.org.uk/guidance/ta789), and who have disease progression after platinum doublet chemotherapy, the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), pemetrexed and carboplatin, or after pemetrexed maintenance, recommended treatment options are:

* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428) (if PD‑L1 above 1%) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta520) (any PD-L1 0% to 100%) or
* the [NICE technology appraisal guidance on nivolumab](https://www.nice.org.uk/guidance/ta713) (if PD-L1 above 1%) or
* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).

For people who have had treatment in line with platinum doublet chemotherapy, the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), pemetrexed and carboplatin, or after pemetrexed maintenance, and who have disease progression after follow-up treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428), [atezolizumab](https://www.nice.org.uk/guidance/ta520) or [nivolumab](https://www.nice.org.uk/guidance/ta713), recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).

## Non-squamous non-small cell lung cancer, BRAF V600 positive, PD‑L1 below 50%

Initial recommended treatment options are:

* platinum doublet chemotherapy or
* the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181) or
* pemetrexed and carboplatin or
* the [NICE technology appraisal guidance on atezolizumab and bevacizumab, carboplatin and paclitaxel](https://www.nice.org.uk/guidance/TA584) or
* the [NICE technology appraisal guidance on pembrolizumab and pemetrexed and platinum chemotherapy](https://www.nice.org.uk/guidance/ta683) or
* the [[NICE technology appraisal guidance on dabrafenib](https://www.nice.org.uk/guidance/ta898) and trametinib](https://www.nice.org.uk/guidance/ta898).

For maintenance treatment for people who have had initial treatment with platinum doublet chemotherapy, the only recommended treatment option is the [NICE technology appraisal guidance on pemetrexed maintenance](https://www.nice.org.uk/guidance/ta190).

For maintenance treatment for people who have had initial treatment in line with the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), the only recommended treatment option is the [NICE technology appraisal guidance on pemetrexed maintenance](https://www.nice.org.uk/guidance/ta402).

Pemetrexed maintenance is a recommended maintenance treatment option for people who have had initial treatment with pemetrexed and carboplatin (NHS England policy).

For people who have disease progression after initial treatment with platinum doublet chemotherapy, the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), pemetrexed and carboplatin, or who have had pemetrexed maintenance, recommended treatment options are:

* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428) (if PD‑L1 above 1%) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta520) (any PD-L1 0% to 100%) or
* the [NICE technology appraisal guidance on nivolumab](https://www.nice.org.uk/guidance/ta713) (if PD-L1 above 1%) or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) or
* docetaxel.

For people who have disease progression after follow-up treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428), [atezolizumab](https://www.nice.org.uk/guidance/ta520) or [nivolumab](https://www.nice.org.uk/guidance/ta713), recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on atezolizumab and bevacizumab, carboplatin and paclitaxel](https://www.nice.org.uk/guidance/TA584) or [pembrolizumab and pemetrexed and platinum chemotherapy](https://www.nice.org.uk/guidance/ta683), recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).

For people who have disease progression after initial treatment in line with the [[NICE technology appraisal guidance on dabrafenib](https://www.nice.org.uk/guidance/ta898) and trametinib](https://www.nice.org.uk/guidance/ta898), recommended treatment options (NHS England policy) are:

* platinum doublet chemotherapy or
* the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181) or
* pemetrexed and carboplatin or
* the [NICE technology appraisal guidance on atezolizumab and bevacizumab, carboplatin and paclitaxel](https://www.nice.org.uk/guidance/TA584).

For maintenance treatment for people who have had treatment with platinum doublet chemotherapy, the only recommended treatment option is the [NICE technology appraisal guidance on pemetrexed maintenance](https://www.nice.org.uk/guidance/ta190).

For maintenance treatment for people who have had treatment in line with the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), the only recommended treatment option is the [NICE technology appraisal guidance on pemetrexed maintenance](https://www.nice.org.uk/guidance/ta402).

Pemetrexed maintenance is a recommended maintenance treatment option for people who have had treatment with pemetrexed and carboplatin (NHS England policy).

For people who have had initial treatment in line with the [[NICE technology appraisal guidance on dabrafenib](https://www.nice.org.uk/guidance/ta898) and trametinib](https://www.nice.org.uk/guidance/ta898) and who have disease progression after treatment with platinum doublet chemotherapy, the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), pemetrexed and carboplatin, or who have had pemetrexed maintenance, recommended treatment options are:

* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428) (if PD‑L1 above 1%) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta520) (any PD-L1 0% to 100%) or
* the [NICE technology appraisal guidance on nivolumab](https://www.nice.org.uk/guidance/ta713) (if PD-L1 above 1%) or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy) or
* docetaxel.

For people who have disease progression after follow-up treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428), [atezolizumab](https://www.nice.org.uk/guidance/ta520) or [nivolumab](https://www.nice.org.uk/guidance/ta713), recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).

For people who have had initial treatment in line with the [[NICE technology appraisal guidance on dabrafenib](https://www.nice.org.uk/guidance/ta898) and trametinib](https://www.nice.org.uk/guidance/ta898) and who have disease progression after treatment in line with the [NICE technology appraisal guidance on atezolizumab and bevacizumab, carboplatin and paclitaxel](https://www.nice.org.uk/guidance/TA584), recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).

## Non-squamous non-small cell lung cancer, BRAF V600 positive, PD‑L1 50% or higher

Initial recommended treatment options are:

* the [NICE technology appraisal guidance on pembrolizumab and pemetrexed and platinum chemotherapy](https://www.nice.org.uk/guidance/ta683) or
* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta531) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta705) or
* the [[NICE technology appraisal guidance on dabrafenib](https://www.nice.org.uk/guidance/ta898) and trametinib](https://www.nice.org.uk/guidance/ta898).

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab and pemetrexed and platinum chemotherapy](https://www.nice.org.uk/guidance/ta683), recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta531) or [atezolizumab](https://www.nice.org.uk/guidance/ta705), recommended treatment options (NHS England policy) are:

* platinum doublet chemotherapy or
* the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181) or
* pemetrexed and carboplatin.

For maintenance treatment for people who have had treatment with platinum doublet chemotherapy, the only recommended treatment option is the [NICE technology appraisal guidance on pemetrexed maintenance](https://www.nice.org.uk/guidance/ta190).

For maintenance treatment for people who have had treatment in line with the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), the only recommended treatment option is the [NICE technology appraisal guidance on pemetrexed maintenance](https://www.nice.org.uk/guidance/ta402).

Pemetrexed maintenance is a recommended maintenance treatment option for people who have had treatment with pemetrexed and carboplatin (NHS England policy).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta531) or [atezolizumab](https://www.nice.org.uk/guidance/ta705) and who have disease progression after treatment with platinum doublet chemotherapy, the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), pemetrexed and carboplatin, or who have had pemetrexed maintenance, recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on dabrafenib](https://www.nice.org.uk/guidance/ta898) and trametinib, recommended treatment options (NHS England policy) are:

* the [NICE technology appraisal guidance on atezolizumab and bevacizumab, carboplatin and paclitaxel](https://www.nice.org.uk/guidance/TA584) or
* platinum doublet chemotherapy or
* the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181) or
* pemetrexed and carboplatin.

For people who have had initial treatment in line with the [NICE technology appraisal guidance on dabrafenib](https://www.nice.org.uk/guidance/ta898) and trametinib and who have disease progression after treatment in line with the [NICE technology appraisal guidance on atezolizumab and bevacizumab, carboplatin and paclitaxel](https://www.nice.org.uk/guidance/TA584), recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).

For maintenance treatment for people who have had treatment with platinum doublet chemotherapy, the only recommended treatment option is the [NICE technology appraisal guidance on pemetrexed maintenance](https://www.nice.org.uk/guidance/ta190).

For maintenance treatment for people who have had treatment in line with the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), the only recommended treatment option is the [NICE technology appraisal guidance on pemetrexed maintenance](https://www.nice.org.uk/guidance/ta402).

Pemetrexed maintenance is a recommended maintenance treatment option for people who have had treatment with pemetrexed and carboplatin (NHS England policy).

For people who have had initial treatment in line with the [[NICE technology appraisal guidance on dabrafenib](https://www.nice.org.uk/guidance/ta898) and trametinib](https://www.nice.org.uk/guidance/ta898) and who have disease progression after treatment with platinum doublet chemotherapy, the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), pemetrexed and carboplatin, or who have had pemetrexed maintenance, recommended treatment options are:

* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428) (if PD‑L1 above 1%) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta520) (any PD-L1 0% to 100%) or
* the [NICE technology appraisal guidance on nivolumab](https://www.nice.org.uk/guidance/ta713) (if PD-L1 above 1%) or
* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).

For people who have disease progression after follow-up treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428), [atezolizumab](https://www.nice.org.uk/guidance/ta520), or [nivolumab](https://www.nice.org.uk/guidance/ta713), recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).

## Non-squamous non-small cell lung cancer, ROS-1 positive

Initial recommended treatment options are:

* the [NICE technology appraisal guidance on crizotinib](https://www.nice.org.uk/guidance/TA529) (available through the Cancer Drugs Fund) or
* the [NICE technology appraisal guidance on entrectinib](https://www.nice.org.uk/guidance/TA643).

For people who have disease progression after treatment in line with the [NICE technology appraisal guidance on crizotinib](https://www.nice.org.uk/guidance/TA529) or [entrectinib](https://www.nice.org.uk/guidance/TA643), recommended treatment options are:

* platinum doublet chemotherapy or
* the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181) or
* pemetrexed and carboplatin or
* the [NICE technology appraisal guidance on atezolizumab and bevacizumab, carboplatin and paclitaxel](https://www.nice.org.uk/guidance/TA584) (NHS England policy).

For maintenance treatment for people who have had treatment with platinum doublet chemotherapy, the only recommended treatment option is the [NICE technology appraisal guidance on pemetrexed maintenance](https://www.nice.org.uk/guidance/ta190).

For maintenance treatment for people who have had treatment in line with the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), the only recommended treatment option is the [NICE technology appraisal guidance on pemetrexed maintenance](https://www.nice.org.uk/guidance/ta402).

Pemetrexed maintenance is a recommended maintenance treatment option for people who have had initial treatment with pemetrexed and carboplatin (NHS England policy).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on crizotinib](https://www.nice.org.uk/guidance/TA529) or [entrectinib](https://www.nice.org.uk/guidance/TA643) and who have disease progression after follow-up treatment with platinum doublet chemotherapy, the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), pemetrexed and carboplatin, or after pemetrexed maintenance, recommended treatment options are:

* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428) (if PD‑L1 above 1%) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta520) (any PD-L1 0% to 100%) or
* the [NICE technology appraisal guidance on nivolumab](https://www.nice.org.uk/guidance/ta713) (if PD-L1 above 1%) or
* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).

For people who have disease progression after treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428), [atezolizumab](https://www.nice.org.uk/guidance/ta520) or [nivolumab](https://www.nice.org.uk/guidance/ta713), recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on atezolizumab and bevacizumab, carboplatin and paclitaxel](https://www.nice.org.uk/guidance/TA584), recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).

## Non-squamous non-small cell lung cancer, EGFR-TK positive

Initial recommended treatment options are:

* the [NICE technology appraisal guidance on afatinib](https://www.nice.org.uk/guidance/TA310) or
* the [NICE technology appraisal guidance on dacomitinib](https://www.nice.org.uk/guidance/TA595) or
* the [NICE technology appraisal guidance on erlotinib](https://www.nice.org.uk/guidance/TA258) or
* the [NICE technology appraisal guidance on gefitinib](https://www.nice.org.uk/guidance/TA192) or
* the [NICE technology appraisal guidance on osimertinib](https://www.nice.org.uk/guidance/TA654) or
* platinum doublet chemotherapy.

For people who have disease progression after initial treatment with platinum doublet chemotherapy, recommended treatment options are:

* the [NICE technology appraisal guidance on afatinib](https://www.nice.org.uk/guidance/TA310) or
* the [NICE technology appraisal guidance on erlotinib](https://www.nice.org.uk/guidance/TA374).

For people who are T970M positive and have disease progression after initial treatment in line with the [NICE technology appraisal guidance on afatinib](https://www.nice.org.uk/guidance/TA310), [dacomitinib](https://www.nice.org.uk/guidance/TA595), [erlotinib](https://www.nice.org.uk/guidance/TA258) or [gefitinib](https://www.nice.org.uk/guidance/TA192), the only recommended treatment option is the [NICE technology appraisal guidance on osimertinib](https://www.nice.org.uk/guidance/TA653).

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on afatinib](https://www.nice.org.uk/guidance/TA310), [dacomitinib](https://www.nice.org.uk/guidance/TA595), [erlotinib](https://www.nice.org.uk/guidance/TA258), [gefitinib](https://www.nice.org.uk/guidance/TA192) or [osimertinib](https://www.nice.org.uk/guidance/TA654), or after follow-up treatment with [osimertinib](https://www.nice.org.uk/guidance/TA653) (for people who are T970M positive), recommended treatment options are:

* platinum doublet chemotherapy or
* the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181) (NHS England policy) or
* pemetrexed and carboplatin or
* the [NICE technology appraisal guidance on atezolizumab and bevacizumab, carboplatin and paclitaxel](https://www.nice.org.uk/guidance/TA584).

For people who have disease progression after treatment in line with the [NICE technology appraisal guidance on atezolizumab and bevacizumab, carboplatin and paclitaxel](https://www.nice.org.uk/guidance/TA584), recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).

For maintenance treatment for people who have had follow-up treatment with platinum doublet chemotherapy, the only recommended treatment option is the [NICE technology appraisal guidance on pemetrexed maintenance](https://www.nice.org.uk/guidance/ta190).

For maintenance treatment for people who have had follow-up treatment in line with the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), the only recommended treatment option is the [NICE technology appraisal guidance on pemetrexed maintenance](https://www.nice.org.uk/guidance/ta402).

Pemetrexed maintenance is a recommended maintenance treatment option for people who have had follow-up treatment with pemetrexed and carboplatin (NHS England policy).

For people who have disease progression after follow-up treatment with platinum doublet chemotherapy, the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), pemetrexed and carboplatin, or after pemetrexed maintenance, or after initial platinum doublet chemotherapy and follow-up treatment in line with the [NICE technology appraisal guidance on afatinib](https://www.nice.org.uk/guidance/TA310) or [erlotinib](https://www.nice.org.uk/guidance/TA374), recommended treatment options are:

* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428) (if PD‑L1 above 1%) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta520) (any PD-L1 0% to 100%) or
* the [NICE technology appraisal guidance on nivolumab](https://www.nice.org.uk/guidance/ta713) (if PD-L1 above 1%) or
* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).

For people who have disease progression after treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428), [atezolizumab](https://www.nice.org.uk/guidance/ta520) or [nivolumab](https://www.nice.org.uk/guidance/ta713), recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).

## Non-squamous non-small cell lung cancer, ALK positive

Initial recommended treatment options are:

* the [NICE technology appraisal guidance on brigatinib](https://www.nice.org.uk/guidance/TA670) or
* the [NICE technology appraisal guidance on alectinib](https://www.nice.org.uk/guidance/TA536) or
* the [NICE technology appraisal guidance on ceritinib](https://www.nice.org.uk/guidance/TA500) or
* the [NICE technology appraisal guidance on crizotinib](https://www.nice.org.uk/guidance/TA406) or
* platinum doublet chemotherapy.

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on brigatinib](https://www.nice.org.uk/guidance/TA670), [alectinib](https://www.nice.org.uk/guidance/TA536) or [ceritinib](https://www.nice.org.uk/guidance/TA500), the only recommended treatment option is the [NICE technology appraisal guidance on lorlatinib](https://www.nice.org.uk/guidance/TA628) (NHS England policy for follow-up treatment to brigatinib).

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on crizotinib](https://www.nice.org.uk/guidance/TA406), recommended treatment options are:

* the [NICE technology appraisal guidance on brigatinib](https://www.nice.org.uk/guidance/TA571) or
* the [NICE technology appraisal guidance on ceritinib](https://www.nice.org.uk/guidance/TA395).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on crizotinib](https://www.nice.org.uk/guidance/TA406) and who have disease progression after follow-up treatment in line with the [NICE technology appraisal guidance on brigatinib](https://www.nice.org.uk/guidance/TA571) or [ceritinib](https://www.nice.org.uk/guidance/TA500), the only recommended treatment option is the [NICE technology appraisal guidance on lorlatinib](https://www.nice.org.uk/guidance/TA628).

For people who have disease progression after treatment in line with the [NICE technology appraisal guidance on lorlatinib](https://www.nice.org.uk/guidance/TA628), recommended treatment options are:

* platinum doublet chemotherapy or
* the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181) (NHS England policy) or
* pemetrexed and carboplatin or
* the [NICE technology appraisal guidance on atezolizumab and bevacizumab, carboplatin and paclitaxel](https://www.nice.org.uk/guidance/TA584).

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on atezolizumab and bevacizumab, carboplatin and paclitaxel](https://www.nice.org.uk/guidance/TA584), recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).

For maintenance treatment for people who have had treatment in line with the [NICE technology appraisal guidance on lorlatinib](https://www.nice.org.uk/guidance/TA628), followed by treatment with platinum doublet chemotherapy, the only recommended treatment option is the [NICE technology appraisal guidance on pemetrexed maintenance](https://www.nice.org.uk/guidance/ta190).

For maintenance treatment for people who have had treatment in line with the [NICE technology appraisal guidance on lorlatinib](https://www.nice.org.uk/guidance/TA628), followed by treatment in line with the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), the only recommended treatment option is the [NICE technology appraisal guidance on pemetrexed maintenance](https://www.nice.org.uk/guidance/ta402).

Pemetrexed maintenance is a recommended maintenance treatment option for people who have had treatment in line with the [NICE technology appraisal guidance on lorlatinib](https://www.nice.org.uk/guidance/TA628) followed by treatment with pemetrexed and carboplatin (NHS England policy).

For people who have had treatment in line with the [NICE technology appraisal guidance on lorlatinib](https://www.nice.org.uk/guidance/TA628) and who have disease progression after follow-up treatment with platinum doublet chemotherapy, the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), pemetrexed and carboplatin, or after pemetrexed maintenance, recommended treatment options are:

* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428) (if PD‑L1 above 1%) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta520) (any PD-L1 0% to 100%) or
* the [NICE technology appraisal guidance on nivolumab](https://www.nice.org.uk/guidance/ta713) (if PD-L1 above 1%) or
* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).

For people who have disease progression after treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428), [atezolizumab](https://www.nice.org.uk/guidance/ta520) or [nivolumab](https://www.nice.org.uk/guidance/ta713), recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).

For people who have disease progression after initial treatment with platinum doublet chemotherapy, the recommended treatment options are:

* the [NICE technology appraisal guidance on crizotinib](https://www.nice.org.uk/guidance/TA422) or
* the [NICE technology appraisal guidance on brigatinib](https://www.nice.org.uk/guidance/ta670).

For people who have had initial treatment with platinum doublet chemotherapy and who have disease progression after follow-up treatment in line with the [NICE technology appraisal guidance on crizotinib](https://www.nice.org.uk/guidance/TA422), the recommended treatment options are:

* the [NICE technology appraisal guidance on brigatinib](https://www.nice.org.uk/guidance/ta571) or
* the [NICE technology appraisal guidance on ceritinib](https://www.nice.org.uk/guidance/ta395).

For people who have had initial treatment with platinum doublet chemotherapy followed by treatment in line with the [NICE technology appraisal guidance on brigatinib](https://www.nice.org.uk/guidance/ta670), or treatment in line with the [NICE technology appraisal guidance on crizotinib](https://www.nice.org.uk/guidance/TA422) followed by the [NICE technology appraisal guidance on brigatinib](https://www.nice.org.uk/guidance/ta571) or [ceritinib](https://www.nice.org.uk/guidance/ta395), recommended treatment options are:

* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428) (if PD‑L1 above 1%) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta520) (any PD-L1 0% to 100%) or
* the [NICE technology appraisal guidance on nivolumab](https://www.nice.org.uk/guidance/ta713) (if PD-L1 above 1%) or
* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).

For people who have disease progression after treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta428), [atezolizumab](https://www.nice.org.uk/guidance/ta520) or [nivolumab](https://www.nice.org.uk/guidance/ta713), recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).